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Abstract 
Mutations in the SOD1 gene are associated with some forms of familial ALS (fALS). There are 
over 150 different mutations in the SOD1 gene which cause various effects to the SOD1 enzyme 
structure, including loss of metal binding and a decrease in dimer affinity. The copper-based 
therapeutic CuATSM has been proven to be effective at rescuing neuronal cells from SOD1 mutant 
toxicity, and has also increased the life expectancy of mice expressing the human transgenes 
SOD1G93A and SOD1G37R. Furthermore, CuATSM is currently the subject of a phase I/II clinical 
trial in Australia as a treatment for ALS. In order to determine if CuATSM protects against a broad 
variety of SOD1 mutations, we used a well-established cell culture model of SOD1-fALS. NSC-
34 cells expressing SOD1-EGFP constructs were treated with CuATSM and examined by time 
lapse microscopy. Our results show a concentration dependent protection of cells expressing 
mutant SOD1A4V over the experimental time period. We tested the efficacy of CuATSM on ten 
SOD1-fALS mutants and found that while protection was observed in cells expressing pathogenic 
wild type-like mutants, cells expressing a truncation mutant or metal binding region mutants were 
not. We also show that CuATSM rescue is associated with an increase in human SOD1 activity 
and a decrease in SOD1 aggregation in vitro. In conclusion, CuATSM has shown to be a promising 
therapeutic for SOD1-associated ALS, however, our in vitro results suggest that the protection 
afforded varies depending on the SOD1 variant, including negligible protection to mutants with 
deficient copper binding.    
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Graphical Abstract  
 
   
 
Introduction 
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease and is the most 
common type of Motor Neuron Disease. ALS causes loss of muscle control and eventually leads 
to death due to respiratory failure, generally within 3-5 years after diagnosis1. These symptoms 
manifest due to the degeneration of upper and lower motor neurons in the motor cortex and spinal 
cord. The lifetime risk for ALS is ~1:300 to 1:4002, and currently there are no effective treatments. 
Most cases of ALS are sporadic (sALS), however, approximately 10% are inherited. These familial 
cases (fALS) are linked to mostly missense mutations in over a dozen genes, including SOD13, 
TARDBP4, FUS5,6 and CCNF7. Furthermore, the most common genetic cause of ALS results from 
hexanucleotide repeats in non-coding regions of the C9ORF72 gene8,9. 
 
SOD1 was the first gene identified to contain mutations associated with fALS3 and is the most 
widely studied of the currently known ALS-associated genes. Over 150 (mostly missense) 
mutations occurring throughout the protein sequence are currently thought to be fALS causative, 
with these mutations being responsible for ~20% of fALS cases10. The SOD1 gene encodes an 
antioxidant enzyme, copper-zinc superoxide dismutase (SOD1), which functions as a cytosolic 
free radical scavenger. The protein has a homodimeric structure where monomers contain an 
intramolecular disulfide bond and also bind one copper (Cu) atom and one zinc (Zn) atom11. The 
maturation pathway of SOD1 is thought to proceed through Zn binding to the nascent 
polypeptide12, followed by association with the copper chaperone for SOD1 (CCS), which delivers 
Cu and facilitates disulfide formation13. Cu is essential for its superoxide scavenging role as it 
reacts with oxygen free radicals in the following Cu-dependent reactions14: 
 
1.      O2•- + CuIIZnSOD → O2 + CuIZnSOD 
2.      O2•- + 2H+ + CuIZnSOD → H2O2 + CuIIZnSOD 
  
It was initially thought that loss of enzymatic function was responsible for disease, however, this 
was determined not to be the case as many SOD1-fALS mutants retain enzymatic activity at near 
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wild type levels15. SOD1-fALS mutations are broadly designated into two classes; (i) wild type-
like (WTL), which have similar dismutase activity levels to the wild type protein, and (ii) metal 
binding region (MBR) which are mutations occurring within the metal binding region of SOD1 
that disrupt proper coordination of either Zn or Cu, resulting in decreased folding stability and 
enzymatic activity11. The existence of the WTL mutants suggests that pathology is caused by a 
toxic gain of function, most likely due to the misfolding and subsequent aggregation of mutant 
SOD111. 
 
Growing evidence suggests that there is an association between protein aggregate formation and 
the development of ALS16. In SOD1-fALS it has been shown that affected neurons often have 
proteinaceous inclusions primarily composed of SOD1, and the aggregation propensity of SOD1 
mutants correlate with cell death in vitro17. Also, the prion-like propagation of SOD1 misfolding 
and aggregation has been proposed to explain the progressive nature of the disease18-21. 
Aggregation of the SOD1 enzyme is generally associated with mutations that result in the 
destabilization of the structure from decreased metal binding22, defective disulfide bond 
formation23, increased dimer dissociation24, and monomeric folding stability25. In addition, SOD1 
is significantly metastable in motor neurons owing primarily to its extremely high expression26 
making it prone to aggregation, and it is expected that mutations act to exacerbate this situation.  
 
Recently, the Cu-based small molecule Cu(II)ATSM (CuATSM) has been used experimentally to 
rescue ALS phenotypes in cell and mouse models27-29. Furthermore, human trials are currently 
underway as a potential treatment for ALS26. In separate experiments, CuATSM was shown to 
increase the survival of mice overexpressing the human SOD1 transgene with G37R 28,29 or G93A 
27,30 mutations, both of which are WTL mutants. CuATSM was effective in protecting against 
SOD1-fALS mediated pathology in these experiments, however, since both mutations tested were 
WTL11, whether CuATSM is still effective against MBR mutants is unknown. Therefore, using an 
established cell model of SOD1-related fALS17,31,32, we set out to investigate whether CuATSM 
is protective across a range of ALS-associated SOD1 mutations. In the current work, ten SOD1-
fALS mutations (SOD1A4V, SOD1G127X, SOD1C6G, SOD1G37R, SOD1H46R, SOD1E100G, SOD1D90A, 
SOD1G93A, SOD1V148G and SOD1G85R) and wild type SOD1 (SOD1WT) were used to examine 
mutant specific effects of CuATSM treatment (Figure 1). We found that of these mutants, cells 
expressing SOD1H46R, SOD1G127X and SOD1G85R, all which have disrupted Cu binding, were not 
protected by CuATSM. Further, we found that CuATSM significantly reduces the aggregation of 
pathogenic WTL mutants. These results are consistent with CuATSM delivering Cu to mutant 
SOD1 when Cu binding is not impaired, increasing protein stability, reducing aggregation and 
improving cell survival. 
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Figure 1: SOD1 dimer with post-translational modifications and ALS-associated mutants. (Left 
subunit) The location of the wild-type like (WTL) SOD1 mutants examined in this study (red spheres). 
(Right subunit) Cu (blue sphere) and Zn (green sphere) ions in their native binding sites. The metal-binding 
region (MBR) mutants H46R and G85R (magenta) shown close to the metal-binding pocket. The truncation 
mutant G127X is shown as an orange sphere. The disulfide bond is shown on both subunits (yellow sticks). 
PDB accession: 1HL5 33. 
 
 
Results and Discussion 
The therapeutic benefits of CuATSM have been experimentally proven in multiple models of 
SOD1-fALS27-30, and independently verified in the SOD1-G93A mouse model34, however, the 
exact mechanism of action in these models remains to be elucidated. Previous in vivo studies have 
used CuATSM on SOD1-fALS mice carrying transgenes for the WTL mutants SOD1G37R 29 and 
SOD1G93A 30, however, no experiments have been performed in models expressing SOD1 MBR 
mutants. Here, we have addressed this gap in knowledge by using CuATSM to treat a cell model 
of SOD1-fALS that allowed for rapid comparison of a broad range of mutants, finding that 
CuATSM alleviated pathology only for pathogenic WTL SOD1 mutants. 
 
CuATSM protects NSC-34 cells against mutant SOD1 toxicity in a dose dependent manner. 
CuATSM has been shown to improve survival and locomotor function of SOD1 mice in a dose-
dependent manner29. Here we sought to determine the effect of CuATSM on the survival of a well-
established cell model; NSC-34 cells overexpressing human mutant SOD1-EGFP17,31. Using live-
cell time-lapse microscopy we monitored the survival of NSC-34 cells transiently transfected with 
SOD1WT-EGFP (Figure 2A), SOD1A4V-EGFP (Figure 2B) or EGFP only control (Figure 2C) 
over a 90 h period in the presence of increasing concentrations (0 - 1 µM) of CuATSM. Consistent 
with what has been observed in transgenic SOD1 animal models29, CuATSM increased the 
survival of mutant SOD1 expressing NSC-34 cells in a dose dependent manner. In the absence of 
CuATSM, SOD1A4V-EGFP expression resulted in a significant loss of cells compared to those 
expressing SOD1WT-EGFP. A concentration dependent increase in SOD1A4V-EGFP cell numbers 
was observed post CuATSM treatment, except for at the 1 µM dose which resulted in a loss of 
cells relative to the 0.5 µM dose (Figure 2D). The protection afforded to SOD1A4V-EGFP 
expressing cells by CuATSM was maximal at 0.5 µM. Treatment with 1 µM CuATSM was also 
toxic to cells expressing both SOD1WT-EGFP and EGFP. Therefore, a CuATSM concentration of 
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0.5 μM was selected as the most appropriate dose to examine the toxicity associated with 
overexpression of mutant SOD1 in NSC-34 cells for subsequent experiments. 
 
 
 
Figure 2: The effects of CuATSM on the survival of NSC-34 cells expressing SOD1-EGFP. NSC-34 
cells expressing SOD1WT (A), SOD1A4V (B) and EGFP (C) were treated with 0-1μM CuATSM and images 
were acquired for 90 h every 3 h on a IncuCyte automated fluorescent microscope in the GFP channel. The 
number of GFP positive cells was determined at every time point and first normalized to the starting time 
point after which the value at each time point for mutants was normalized to the number of untreated 
SOD1WT cells at corresponding time points (indicated by the solid straight line in panels B and C). (D) The 
percentage survival of cells expressing SOD1WT, SOD1A4V or EGFP in the presence of 0-1μM CuATSM 
was determined by measuring the area under the GFP count curves and normalizing to SOD1WT in the 
absence of CuATSM. Data shown are means ± SEM (n= 3). Each sample is an individually treated single 
microplate well. Two-way ANOVA with Bonferroni post-test was used to compare differences. Asterisks 
indicate a significant difference to SOD1WT (*p<0.05, ***p < 0.001). 
  
CuATSM does not protect cells expressing SOD1 mutations that disrupt metal binding. 
Although CuATSM has been previously shown to rescue SOD1 mouse models from 
overexpression of either SOD1G37R 28,29 or SOD1G93A 27-30, it has not been tested against other 
5 
SOD1 mutations, some of which are MBR mutations which affect Cu coordination. Having 
determined an effective dose of CuATSM to apply to our model, we transiently transfected NSC-
34 cells with ten different mutant SOD1-EGFP constructs to determine the effect of CuATSM on 
a range of SOD1 mutants, including MBR mutations. 
 
As we have shown previously, expression of human SOD1 mutants result in a loss of cell numbers 
relative to cells expressing SOD1WT 17. An exception to this is the D90A mutation which is 
recessive in some Scandinavian families35. In fact, the pathogenic nature of D90A is contested, 
with some suggesting heterozygosity is enough to cause disease36, while others have found that  as 
many as 2.5% of the Northern Swedish population are carriers, suggesting D90A is not 
pathogenic37. Consistent with this is the fact that some D90A kindreds individuals without the 
mutation inherit ALS38. Our results are consistent with the latter in that expression of SOD1D90A 
did not produce a phenotype, and as such essentially acts as an additional WT control.  In the case 
of cells expressing EGFP fused to SOD1A4V, SOD1C6G, SOD1G37R, SOD1E100G, SOD1G93A, and 
SOD1V148G, the addition of 0.5 μM CuATSM resulted in an increased number of SOD1-EGFP 
positive cells comparative to untreated cells at all time points (Figure 3A). After calculating the 
area under the curve across the entire time course, it is apparent that CuATSM treatment 
significantly improved transfected cell survival for these mutants (Figure 3B). 
 
Cells transfected with MBR mutants SOD1H46R and SOD1G85R also exhibited a loss of transfected 
cells relative to SOD1WT over time. Similarly, the truncation mutant SOD1G127X, that fails to fold 
and thus should not bind metals, also resulted in relative cell loss. However, addition of CuATSM 
did not alter the rate of cell loss (Figure 3A) and no significant differences in cell survival were 
observed with the addition of CuATSM in these mutants (Figure 3B). Cells expressing SOD1D90A, 
EGFP or SOD1WT also were also unaffected by CuATSM but this was most likely due to the fact 
that expression of these constructs did not result in a significant loss of cells when left untreated.  
 
Each pathogenic SOD1 mutant elicited a variable effect on relative NSC-34 cell survival 
(Supplementary Figure 1). In order to compare the amount of protection afforded to each mutant 
by CuATSM, a protection score (% protection) was calculated. The score represents the percentage 
protection CuATSM provides to cells compared to the vehicle control, regardless of differences in 
cell loss from SOD1WT. This allows for direct comparisons across SOD1 variants. The analysis 
confirmed that cells expressing SOD1G127X, SOD1H46R, and SOD1G85R were not protected by 
CuATSM (Figure 3C). Cells expressing SOD1WT, SOD1D90A or EGFP were also not protected by 
CuATSM treatment. For all other SOD1 mutants, CuATSM had a significant protective effect on 
cell survival. Protection scores for these WTL mutants ranged from ~50% (SOD1V148G) to ~85% 
(SOD1G93A), suggesting CuATSM does not provide protection to all WTL mutants equally (Figure 
3C, Supplementary Table 1). However, there was no relationship between protection score and 
associated clinical disease severity (Supplementary Figure 2). 
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The results reported here show that addition of CuATSM to cells expressing MBR SOD1-fALS 
mutants and truncation mutant SOD1G127X does not alleviate the toxicity of these mutant proteins. 
Furthermore, CuATSM does not affect cells expressing EGFP, SOD1D90A, or SOD1WT.  However, 
similar to previously published data from mouse models27-30, we show that CuATSM improves the 
survival of cells expressing pathogenic WTL SOD1 mutants.  
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Figure 3: The effect of CuATSM on the toxicity of different SOD1 variants. (A) NSC-34 cells were 
transfected with SOD1-EGFP constructs and GFP fluorescence was monitored over 120 h in the presence 
and absence of 0.5μM CuATSM. (B) Cell survival compared to cells expressing SOD1WT was determined 
by measuring the area under the curve for each SOD1 variant in the presence and absence of CuATSM over 
the 120 h time period. Data shown are means ± SEM (n= 3). Each sample is an individually treated, single 
microplate well. Data are representative of 3 independent experiments.  Statistical significance was 
determined using two-way ANOVA with Bonferroni post-test (*** p < 0.001). (C) The protection provided 
to cells by CuATSM was determined by calculating the difference between each variant with and without 
CuATSM treatment as a percentage relative to untreated cells. Data shown are means ± SD (n= 3).  Each 
sample is an individually treated, single microplate well. Data are representative of 3 independent 
experiments.  Statistical significance was determined using one-way ANOVA with a Tukey’s multiple 
comparison post-test. Asterisks indicate significant difference to SOD1WT (*** p < 0.001). 
  
CuATSM decreases the aggregation of SOD1 mutants in cultured cells. 
Although SOD1 is a small protein, it requires extensive processing and post-translational 
modification (PTM) to reach maturity13, which includes Zn binding, Cu binding, and disulfide 
formation. These PTMs impart remarkable stability to the enzyme making it resistant to proteolytic 
digestion39, thermal unfolding40, and chemical denaturation41. Removal of these PTMs is 
considered necessary for its misfolding and aggregation42. Indeed, the thermal stability of mature 
mutant SOD1G93A is highly similar to SOD1WT 43, with significant differences between the stability 
of mutants only becoming apparent in the apo-state. Considering this, the availability of additional 
Cu imparted by CuATSM treatment, would be expected to aid CCS in its chaperone function44 
and increase maturation of the pool of intracellular SOD1 to a Cu bound form that is less 
susceptible to misfolding and aggregation.  
 
To test whether CuATSM affects the aggregation of SOD1 in the NSC-34 cell model, cells 
expressing the various SOD1-EGFP constructs were treated with 0.5 μM CuATSM for 72 h before 
permeabilising cell membranes with saponin45,46 to allow the diffusion of soluble protein out of 
the cell and facilitate examination of the insoluble EGFP signal remaining inside the cell47 (Figure 
4A).  The amount of insoluble material (aggregates) remaining inside cells was then quantified as 
a proportion of transfected cells. We found that aggregation varied amongst SOD1 variants with 
as many as 22% of SOD1A4V expressing cells, and ~1% of SOD1WT and SOD1D90A expressing 
cells containing aggregates (Figure 4B). In cells where minimal aggregation occurred, specifically 
EGFP, SOD1WT and SOD1D90A, CuATSM had no significant effect on aggregation.  We also found 
that CuATSM did not significantly reduce the aggregation of  MBR SOD1 mutants SOD1H46R and 
SOD1G85R (1.2 and 1.1 fold reduction in the percentage of cells containing aggregates compared 
to the vehicle control respectively; Figure 4B). Cells expressing the largely unstructured 
SOD1G127X also had a small but significant decrease in aggregation in the presence of CuATSM 
(~ 1.3 fold reduction). In contrast, cells expressing pathogenic WTL mutants all showed a 
significant reduction in cells containing aggregates (on average ~ 3 fold reduction, also see 
Supplementary Table 1) distinguishing them from the MBR mutants and controls (Figure 4B). 
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Although Cu deficiency is associated with increased misfolding of SOD1, it has previously been 
shown that treatment with CuATSM did not reduce the levels of misfolded SOD1 in SOD1G37R 
mice28. Interestingly, CuATSM has been shown to reduce the accumulation of abnormally 
phosphorylated and fragmented TDP-43 in the spinal cords of mice expressing low levels of 
mutant SOD1G93A 48. This may be due to direct effects on SOD1 aggregation as SOD1 aggregates 
have been shown to induce TDP-43 mislocalisation49. Here, we show that CuATSM treatment 
reduces the aggregation of pathogenic WTL SOD1 mutants and has small but nonsignificant 
effects on the aggregation of MBR mutants and a small but significant effect on cells expressing 
SOD1G127X. Similarly, CuATSM does not alter the minimal aggregation in cells expressing 
SOD1D90A, EGFP or SOD1WT. Our data suggests that the primary effect CuATSM has on 
aggregation is to supply Cu to mutant SOD1, thereby stabilizing its structure. The small reductions 
in aggregation observed with mutants unable to bind Cu suggests that CuATSM could also have 
additional indirect effects on aggregation by activating stress pathways via Nrf250, including the 
ubiquitin-proteasome system, but that this modest effect does not extend to cell viability. In the 
case of G127X, there is also a chance that since it retains the Cu-coordinating histidine residues 
(H46, H48, H63, and H120), Cu could be binding with low affinity. This could afford a slight 
increase in stability that plausibly translates to the minimal effect on aggregation observed here.  
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Figure 4: CuATSM decreases the aggregation of WTL SOD1 mutants. (A) NSC-34 cells transfected 
with SOD1WT-EGFP or SOD1A4V-EGFP were imaged by confocal microscopy pre- and post-saponin 
treatment to identify cells containing insoluble SOD1-EGFP aggregates. Scale bars are 20 µm and pink 
arrowheads highlight insoluble aggregates. (B) NSC-34 cells expressing SOD1-EGFP constructs were also 
imaged pre- and post-saponin treatment using an IncuCyte automated microscope to determine the 
proportion of transfected cells that contained SOD1-EGFP inclusions. Data shown are mean ± SEM (n = 
3).  Each sample is an individually treated, single microplate well. Data are representative of 3 independent 
experiments. The fold decrease in the number of cells containing aggregates seen with +CuATSM treatment 
(relative to the vehicle control, -CuATSM) is stated above each mutant. Statistical significance was 
determined by two-way ANOVA with a Bonferroni post-test (** p < 0.01, *** p < 0.001).   
 
CuATSM increases SOD1 levels and activity in WT-like mutants. 
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Previous work demonstrates that administration of CuATSM results in the increase of human 
mutant SOD1 protein levels in mouse models of ALS27,28. The increase in SOD1 protein levels 
also corresponded to an increase in SOD1 activity27 suggesting the additional protein was properly 
folded and metalated. To test whether SOD1 levels and activity were increased by CuATSM in 
the NSC-34 cell model used here, western blotting and in-gel zymography was performed on cell 
lysates from cells cultured in the absence or presence of CuATSM. Cells expressing SOD1WT and 
SOD1A4V and SOD1H46R were compared as examples of WTL and MBR mutants. In-gel 
zymography revealed that CuATSM increased the activity of human SOD1 in the case of cells 
expressing SOD1WT and SOD1A4V (Figure 5, Supplementary Figure 3). Similarly, CuATSM 
increased the activity of SOD1D90A and all pathogenic WTL mutants tested (Supplementary 
Figure 3).  However, SOD1A4V remained predominantly monomeric regardless of treatment. This 
increase in activity was accompanied by increases in protein levels as determined by western blot 
(Figure 6, Supplementary Figure 4). In contrast, SOD1H46R was inactive in both the presence 
and absence of CuATSM (Figure 5B), and there was no difference in protein levels after treatment 
with CuATSM (Figure 6B). In-gel zymography results also indicate that the MBR mutant 
SOD1G85R and truncation mutant SOD1G127X remain inactive regardless of CuATSM treatment 
(Supplementary Figure 3). 
 
 
Figure 5. CuATSM increases the activity of WT-like SOD1 mutants. (A) Lysates from NSC-34 cells 
overexpressing SOD1WT, SOD1A4V and SOD1H46R were separated on native 4-16% gradient bis-tris gels 
and SOD1 activity was determined by in-gel zymography. Equal loading was determined by measuring 
endogenous mouse SOD1 on the same gel. (B). Quantification of SOD1 activity expressed relative to 
endogenous mouse SOD1 levels. Data shown are mean ± SEM (n = 3). Data is from 3 independent 
experiments. Two-way ANOVA with Bonferroni post-test was used to compare differences between cell 
lysates cultured in the presence and absence of CuATSM (**p<0.01). 
 
Large pools of Cu-deficient SOD1 have been detected in the spinal cords of SOD1G37R mice and 
treatment with CuATSM reduced this pool and subsequently increased the amount of fully 
metalated SOD128. Here we show that CuATSM treatment increases the concentration of active 
enzyme and reduces the aggregation of SOD1 mutants in NSC-34 cells. These results suggest that, 
in our system, overexpression of pathogenic WTL SOD1 mutants exceeds basal Cu demands of 
the cell, creating a pool of Cu deficient SOD1 which misfolds and aggregates. Interestingly, 
overexpression of SOD1WT and SOD1D90A also results in a pool of Cu deficient SOD1 as treatment 
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with CuATSM increases human SOD1 activity in NSC-34 cells, however, this does not result in 
aggregation and toxicity. This is consistent with the notion that a misfolded conformer is required 
for toxicity and not Cu deficiency per se. While our results suggest that misfolding and aggregation 
are the common attributes of WTL and MBR mutants that are associated with toxicity, Cu 
deficiency could result in the misfolding of SOD1 and subsequent aggregation and toxicity. 
Indeed, as aggregated SOD1 propagates in a prion-like fashion18-21, increasing the availability of 
Cu to cells could reduce the pool of misfolded SOD1 required for template driven aggregation and 
thus propagation. 
 
 
 
Figure 6. CuATSM increases the levels of WT-like SOD1 mutants. (A) Cell lysates from NSC-34 cells 
overexpressing SOD1WT, SOD1A4V and SOD1H46R were separated on native 4-16% gradient bis-tris gels 
and SOD1-EGFP levels were determined by western blot analysis. (B) SOD1-EGFP levels were quantified 
from western blot analyses by densitometry and expressed relative to the average of the total EGFP signal 
for that variant. Data shown are mean ± SEM (n = 3). Data is from 3 independent experiments. Two-way 
ANOVA with Bonferroni post-test was used to compare differences between cell lysates cultured in the 
presence and absence of CuATSM (*p<0.05, ***p<0.001).  
 
 
Copper homeostasis is an area of growing interest in SOD1-fALS research as Cu is found to be 
dysregulated in animal models expressing either WTL or MBR SOD1 mutants51-54. For example, 
Cu levels are found to be increased in affected neural tissues in SOD1-fALS mouse models 
including SOD1G37R, SOD1G93A, SOD1WT, and even in mice expressing the MBR double mutant 
SOD1H46R/H48Q 51-54. This suggests that Cu dysregulation in the central nervous system (CNS) is a 
common feature of SOD1 overexpression. The SOD1-associated Cu dysregulation in these models 
has been shown to affect other Cu-binding proteins such as cytochrome c oxidase30 and 
ceruloplasmin55. Although this effect appears to be partially model-specific as cytochrome c 
oxidase activity was no different to controls in the latter study, this difference is likely due to the 
fact that the hCCS×SOD1G93A model is an extremely severe model of the disease. Furthermore, 
Cu dysregulation appears to occur early in SOD1 mouse models where changes to Cu levels in the 
CNS are detected as early as 30 days of age, well before symptom onset, in SOD1G93A mice56. 
Similarly, the SOD1G37R mouse model experiences a redistribution of Cu from the liver to the CNS 
at the embryonic stages of development, which is not seen in adult mice57, suggesting changes to 
Cu regulation over time in SOD1 mouse models.  
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Considering the above work, there have been several proposals for the molecular mechanism(s) 
by which CuATSM attenuates the ALS phenotype in model systems. These proposals emphasize 
the role of CuATSM in restoring healthy SOD1 folding and function, or they emphasize the role 
of CuATSM in restoring Cu homeostasis to other proteins as well as SOD1. The interpretation is 
made difficult because of the concomitant effects of SOD1 misfolding and Cu dysregulation.  
 
Evidence for a homeostatic role include research in which treating a SOD1G93A mouse model with 
CuATSM was shown to inhibit peroxynitrite activity48. Oxidative and nitrosative stress were also 
found to be reduced, although it is unclear if this resulted from the increased folding of SOD1. 
Also, the transgenic mouse line overexpressing human CCS and SOD1G93A (hCCS×SOD1G93A) 
was found to have severe Cu dyshomeostasis, where treatment with CuATSM restored Cu binding 
to cytochrome c oxidase30. This model also presented the curious observation that levels of 
misfolded SOD1 did not decrease even though levels of Cu-bound SOD1 increased27. Other effects 
of CuATSM not related to the CNS have been reported, such as upregulation of antioxidant 
enzymes in human coronary artery smooth muscle cells and cardiac myocytes through activation 
of the transcription factor NF-E2 related factor 2 (Nrf2)50. Finally, several Parkinson’s disease 
mouse models58 were shown to have better outcomes when treated with CuATSM, consistent with 
the idea that misfolded non-metalated SOD1 is not required for its protective ability in 
neurodegeneration.  
 
 
Figure 7: A model of CuATSM rescue of mutant SOD1 pathology.  Red arrows show the folding and 
off-folding pathways for SOD1, whereas blue arrows show the contribution of CuATSM to these pathways. 
Arrow thickness suggests the probability of the pathways occurring. Following synthesis, mutant SOD1 
(red start) folds into an intermediate state that is primed for Zn binding. Zn bound SOD1 associates with 
Cu-loaded CCS for transfer of Cu, leading to the formation of a mature SOD1 monomer that can form 
dimers. CuATSM results in a larger pool of Cu bound CCS which in turn results in greater transfer of Cu 
to SOD1, reducing the amount of SOD1 that enters an off-folding pathway at this point. 
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Our results, however, indicate distinct differences between MBR, a truncation mutation and 
pathogenic WTL mutants regarding the effect of CuATSM on the toxicity, aggregation, and 
maturation of SOD1 mutants in NSC-34 cells (Figure 7). This evidence supports a distinct role of 
CuATSM in alleviating SOD1 aggregation and toxicity only for mutants that are capable of being 
rescued. However, cultured cells do not effectively model the CNS, and it is likely that CuATSM 
has multiple modes of action in the complex environment of the brain, including on cell types other 
than neurons (e.g. astrocytes59). Future work examining the effect of CuATSM in SOD1 MBR 
mutant transgenic mouse lines will be needed to reconcile these data. Furthermore, the role of 
metals in neurodegeneration is still unclear. Most data linking aberrant metal interactions to 
neurodegeneration in humans comes from ecological and occupational studies60. It is possible that 
metal homeostasis, like proteostasis, declines or changes with age. More research into this 
important area is necessary to determine the exact links between neurodegeneration and metal 
homeostasis.  
 
Conclusions 
Our results suggest that CuATSM is protective against toxicity mediated by a range of pathogenic 
WTL SOD1 mutants but not in the case of MBR mutants or a truncation mutant in a cell culture 
system. These results may be relevant for the design of future clinical trials of CuATSM for MND 
patients, as the disease type (fALS or sALS), and specific SOD1 mutations linked to the fALS 
case, may both impact on the efficacy of the treatment. 
 
 
Methods 
 
Plasmids. The pEGFP-N1 vectors containing human SOD1 sequences were generated as 
described61.  
 
Cell culture and transfection. Neuroblastoma × Spinal cord hybrid NSC-34 cells62 were 
maintained in Dulbecco’s Modified Eagles Medium/ Ham’s Nutrient Mixture F12 (DMEM/F12) 
supplemented with 10% (v/v) foetal bovine serum (FBS, Bovogen Biologicals, Australia). Cells 
were maintained at 37 °C in a humidified incubator with 5% (v/v) atmospheric CO2. Cells were 
transiently transfected using Lipofectamine 3000 (Invitrogen, USA) according to manufacturer’s 
instructions with 0.5 μg DNA per well for a 24-well plate and 2.5 μg DNA per well for 6-well 
plates. 
 
CuATSM treatment. Cu(II)ATSM (SYNthesis med chem, Parkville, VIC, Australia) was 
dissolved in DMSO to make a 10 mM stock. NSC-34 cells were treated with 0 - 1 µM CuATSM 
or DMSO vehicle control (diluted in culture medium) 24 h post transfection for up to 120 h. 
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Time lapse imaging. The viability of cells expressing SOD1 in the presence and absence of 
CuATSM was monitored over 120 h in an IncuCyte automated fluorescent microscope (Essen 
BioScience, USA) as described in17.  NSC-34 cells were plated into 24-well plates at a confluency 
of ~ 65% and transfected with SOD1-EGFP constructs 24 h later. Cells were dissociated 24 h post 
transfection and replated in clear flat-bottomed 96-well plates at a confluency of 30% in phenol 
red free DMEM/F12 containing 10% FBS and 0 - 1 µM CuATSM or vehicle control (DMSO).  
Images were acquired every 3 h and analysed using a processing definition created to select GFP 
positive cells. The number of GFP positive cells was normalized to time zero before mutant SOD1 
numbers were adjusted to SOD1WT values as previously reported17. To analyze differences 
between treatments, area under the curve analysis was performed using GraphPad Prism version 
5.00 for Windows (GraphPad software, USA). The percent protection score was calculated from 
GFP count data normalized to t = 0 h, where the area under the curve (AUC) from t = 0 -72 h was 
calculated for both vehicle control and CuATSM treated cells. The follow equation was used: 
 
% 𝑃𝑟𝑜𝑡𝑒𝑐𝑡𝑖𝑜𝑛 = 100 ×
(𝐴𝑈𝐶 𝐶𝑢𝐴𝑇𝑆𝑀) − (𝐴𝑈𝐶 𝑉𝑒ℎ𝑖𝑐𝑙𝑒)
(𝐴𝑈𝐶 𝑉𝑒ℎ𝑖𝑐𝑙𝑒)
 
 
Saponin treatment to detect insoluble aggregates. NSC-34 cells expressing SOD1-EGFP were 
gently treated 72 h post transfection with 0.03% saponin in PBS to allow the diffusion of soluble 
intracellular SOD1-EGFP out of the cytoplasm to identify cells containing SOD1 aggregates45,46. 
Cells were imaged pre and post saponin treatment on a TCS SP5 confocal microscope (Leica, 
Germany) or by using the scan on demand function on the IncuCyte and the number of cells 
containing aggregates was determined as a proportion of GFP expressing cells. 
 
Cell lysis. NSC-34 cells grown in 6-well plates and transfected with SOD1-EGFP were harvested 
48 h post CuATSM treatment (72 h post transfection) with trypsin/EDTA (Gibco, USA). Cells 
were washed with PBS before being resuspended in RIPA buffer (50 mM TrisHCl pH 7.4, 1% 
(w/v) sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1% TX-100, 0.1% SDS, 10mM NEM, 
1 mM sodium orthovanadate, HaltTM Protease Inhibitor Cocktail (Thermo Scientific, USA)). 
Protein concentration was determined by BCA assay. 
 
SOD1 In-gel zymography.  SOD1 enzymatic activity was determined using in-gel zymography 
methods described previously63. Briefly, 30 µg of cell lysate or 100 ng of purified SOD1WT protein 
(prepared as previously described17) was loaded onto a NativePAGETM 4-16% gradient bis-tris gel 
(Invitrogen, USA). Following electrophoresis (150 V, 3 h), gels were incubated in 5 mM 
nitrotetrazolium chloride for 15 min with gentle rocking protected from the light. Gels were then 
rinsed with water before incubation with 30 µM riboflavin and 10 mM tetramethylethylenediamine 
(TEMED) solution for 20 min with gentle rocking in the dark. Gels were subsequently developed 
by exposure to fluorescent light on a light box until a significant signal was detected (achromatic 
bands). Gels were imaged on the Amersham Imager  6600RGB and band intensity was quantified 
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using ImageJ 1.48v software64. SOD1-EGFP activity was subsequently determined after 
normalizing signal to purified SOD1 and endogenous mouse SOD1 levels.  
  
Western blotting. Following in-gel zymography, proteins were transferred onto a nitrocellulose 
membrane (Pall Corporation, USA) using native transfer buffer (48 mM Tris, 39 mM glycine, pH 
9.2 containing 0.04% (w/v) SDS). The membrane was then incubated in native transfer buffer 
containing 20% methanol before detecting GFP signal by fluorescence (excitation at 460nm) on 
the Amersham Imager 6600RGB. Equal loading of the gel was determined by staining membranes 
with Ponceau red. 
 
Statistical analyses. Normally distributed data sets were analyzed for statistical significance via 
the following tests: one-way ANOVA with a Tukey’s multiple comparison post-test when 
comparing the means of multiple data sets, and two-way ANOVA with Bonferroni post-test when 
assessing multiple variables. 
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Supplementary Table 1. Summary of SOD1 mutant characteristics and the effect of CuATSM 
measured in this paper 
SOD1 
Mutant 
and class 
Mutation Effects on 
stability (apo S-S state) 
compared to wild type 
Mutation 
Effect on 
metal binding 
Mutation Toxicity 
(% survival 
compared to WT) 
CuATSM 
Protection Score  
(% protection) 
Fold reduction 
in aggregation 
by CuATSM 
Mean Disease 
Duration 
(years) 
A4V 
WTL 
↓↓↓- Monomer 
↓↓↓↓ Dimer 
↓--- Zn 
↓↓-- Cu 
35.7 69.4 2.8 1.2 
(n=205) 
C6G 
WTL 
(n/a) Monomer 
(n/a) Dimer 
(n/a) Zn 
(n/a) Cu 
45.3 57.4 3.4 0.2 
(n=2) 
G37R 
WTL 
↓↓-- Monomer 
↓↓-- Dimer 
↓--- Zn 
↓--- Cu 
42.2 81.6 3.3 17.0 
(n=37) 
H46R 
MBR 
↑--- Monomer  
---- Dimer 
↓--- Zn 
↓↓↓↓ Cu 
59.7 - 2.5 1.2 17.6 
(n=49) 
G85R 
MBR 
↓↓↓- Monomer 
↓↓↓- Dimer 
↓↓-- Zn 
↓↓↓- Cu 
33.6 0.7 1.1 6.0 
(n=11) 
D90A 
WTL 
↓--- Monomer 
---- Dimer 
---- Zn 
---- Cu 
93.0 - 1.6 1.2 8.0* 
(n=15) 
G93A 
WTL 
↓↓↓- Monomer 
↓↓↓- Dimer 
---- Zn 
---- Cu 
36.1 85.9 2.5 3.1 
(n=16) 
E100G 
WTL 
↓↓-- Monomer 
↓↓-- Dimer 
---- Zn 
---- Cu 
44.5 80.0 3.5 4.7 
(n=50) 
G127X 
truncation 
↓↓↓↓ Monomer 
↓↓↓↓ Dimer 
(n/a) Zn 
(n/a) Cu 
30 - 6.6 1.3 2.8 
(n=3) 
V148G 
WTL 
↓↓↓- Monomer 
↓↓↓- Dimer 
(n/a) Zn 
(n/a) Cu 
39.1 53.6 2.2 2.1 
(n=11) 
References for SOD1 stabilities - 1-3 
References for SOD1 metalation - 4-6 
References for SOD1-fALS survival - 7,8 
 
* the clinical severity of heterozygous D90A mutation is contested with some arguing its clinical 
relevance9 and others that it is a common variant in some populations10, while others argue another 
genetic element is responsible for ALS in D90A kindreds11.   
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Supplementary Figure 1: Correlations of patient mean disease duration against cell survival and 
inclusion formation. The mean values of patient survival were taken from Wang et al (2008)7 and plotted 
against the mean values from the data collected in this work for cell survival (left) and cells containing 
inclusions (right). Solid lines indicate the fit through all SOD1 mutant data points, whereas dotted lines 
indicate the removal of D90A and C6G from the fit. Data were fitted with least squares linear regression 
and the R2 and p values are shown on each panel. 
 
 
 
Supplementary Figure 2: Patient disease duration does not correlate with CuATSM protection. The 
mean values of patient survival were taken from Wang et al (2008)7 and plotted against the percent 
protection values from the data collected in this work for only WT-like mutants (solid line) and all mutants 
(dotted line). Data were fitted with least squares linear regression and the R2 and p values are shown next 
to each fit. 
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Supplementary Figure 3: (A) Cell lysates from NSC-34 cells overexpressing SOD1-GFP, as well as 
untransfected cells (UT) and purified SOD1WT protein were separated on native 4-16% gradient bis-tris gels 
and SOD1 activity was determined by in-gel zymography. (B) Levels of SOD1 activity were also 
determined for cell lysates expressing SOD1C6G, SOD1D90A, SOD1E100G, SOD1G37R, SOD1G93A, SOD1G85R, 
SOD1G127X and SOD1V148G by in-gel zymography. Data shown are for n = 1. 
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Supplementary Figure 4: (A) Representative western blot image of the effects of CuATSM treatment on 
SOD1 levels in cell lysates from NSC-34 cells overexpressing SOD1WT, SOD1A4V, or SOD1H46R, as well as 
untransfected cells (UT) and purified SOD1WT protein separated on a native 4-16% gradient bis-tris gel. (B) 
Equal loading of the gel was determined by staining the membrane with ponceau red. 
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